Table 2.
Summary of the data sources of treatment effects, costs, and utility in the included cost-effectiveness analyses assessing bortezomib or bortezomib-contained regimens for multiple myeloma
| Treatment setting | Comparison | Included studies | Data source for treatment effects | Data sources for costs | Data source for utility |
|---|---|---|---|---|---|
| Induction treatment prior to SCT | BTZ treatment versus non-BTZ treatment | Kouroukis et al12 | IFM2005-01 trial | Medical costs for chemotherapy, maintenance therapy, SCT, palliative care, and adverse events | Van Agthoven et al42 |
| VD versus CTD | Mucha et al13 | IFM2005-01 trial | Medical costs for chemotherapy, maintenance therapy, SCT, palliative care, and adverse events | Van Agthoven et al42 | |
| VD versus VAD | Mucha et al13 | IFM2005-01 trial | Medical costs for chemotherapy, maintenance therapy, SCT, palliative care, and adverse events | Van Agthoven et al42 | |
| VTD versus CTD | Mucha et al13 | PETHEMA trial | Medical costs for chemotherapy, maintenance therapy, SCT, palliative care, and adverse events | Van Agthoven et al42 | |
| VTD versus TD | Mucha et al13 | PETHEMA trial | Medical costs for chemotherapy, maintenance therapy, SCT, palliative care, and adverse events | Van Agthoven et al42 | |
| Van Beurden-Tan et al14 | Medical costs for treatment, SCT, and adverse events | Not reported | |||
| Previously untreated MM but ineligible for SCT | VMP versus MP | Rickert et al15 | VISTA trial | Medical costs for treatment, adverse events, disease relapse, and palliative care | Not reported |
| Garrison et al16 | VISTA trial | Medical costs for treatments, adverse events, and second-line treatment | VISTA trial | ||
| Oster et al17 | Palumbo et al,46 San Miguel et al,32 Facon et al,34 Hulin et al,33 Palumbo et al,35 any VISTA trial | Medical costs for treatment and adverse events | Not reported | ||
| Yoong et al19 | VISTA trial | Medical costs for treatment and adverse events, maintenance therapy, and second-line treatment | Not reported | ||
| Picot et al18 | VISTA trial and Palumbo et al,46 San Miguel et al,32 Facon et al,34 Hulin et al,33 and Palumbo et al35 | Medical costs for treatment and adverse events, maintenance therapy, and second-line treatment | Study mapping EORTC QLQ-C30 to EQ-5D43 | ||
| VMP versus MPT | Rickert et al15 | VISTA trial and Palumbo et al,46 San Miguel et al,32 Facon et al,34 Hulin et al,33 and Palumbo et al35 | Medical costs for treatment, adverse events, relapse, and palliative care | Not reported | |
| Garrison et al16 | VISTA trial and IFM99-06 trial | Medical costs for treatment, adverse events, and second-line treatment | VISTA trial | ||
| Yoong et al19 | VISTA trial | Medical costs for treatment, adverse events, and second-line treatment | Not reported | ||
| Picot et al18 | VISTA trial and Palumbo et al,46 San Miguel et al,32 Facon et al,34 Hulin et al,33 and Palumbo et al35 | Medical costs for treatment, adverse events, and second-line treatment | Study mapping EORTC QLQ-C30 to EQ-5D43 | ||
| VMP versus MPR-R | Garrison et al16 | VISTA trial and MM-015 trial | Medical costs for treatment, adverse events, and second-line treatment | VISTA trial | |
| Oster et al17 | Palumbo et al,46 San Miguel et al,32 Facon et al,34 Hulin et al,33 and Palumbo et al,35 MM-015, and VISTA trial | Medical costs for treatment, adverse events | Not reported | ||
| VMP versus RD | Cavenagh et al20 | FIRST trial and VISTA trial | Medical costs for drugs, administration, medical care, second- and third-line antimyeloma regimens, and management of toxicity | Not reported | |
| Relapsed/refractory MM | BTZ versus BSC | Bagust et al21 | SUMMIT1 trial | Medical costs for treatment and adverse events | Not reported |
| Mehta et al22 | SUMMIT1 trial | Medical costs for treatment and adverse events | Not reported | ||
| BTZ versus THD | Mehta et al22 | SUMMIT1 trial | Medical costs for treatment and adverse events | Not reported | |
| BTZ versus DEX | Hornberger et al25 | APEX trial, MM-009 trial, and MM-10 trial | Medical costs for treatment and adverse events | Van Agthoven et al42 | |
| Liwing et al27 | APEX trial, MM-009 trial, and MM-10 trial | Medical costs for treatment, adverse events, and palliative care | Not reported | ||
| BTZ versus LEN/DEX | Felix et al23 | APEX trial, MM-009 trial, and MM-10 trial | Not reported | Not reported | |
| Fragoulakis et al24 | APEX trial, MM-009 trial, and MM-10 trial | Medical costs for treatment, adverse events, and palliative care | Van Agthoven et al42 | ||
| Hornberger et al25 | APEX trial, MM-009 trial, and MM-10 trial | Medical costs for treatment, adverse events, and palliative care | Van Agthoven et al42 | ||
| Jiang et al26 | APEX trial, MM-009 trial, and MM-10 trial | Not reported | Not reported | ||
| Liwing et al27 | APEX trial, MM-009 trial, and MM-10 trial | Not reported | Not reported | ||
| Moller et al28 | APEX trial, MM-009 trial, and MM-10 trial | Medical costs for treatment, adverse events, and palliative care | Van Agthoven et al42 |
Abbreviations: BSC, best supportive care; BTZ, bortezomib; CTD, cyclophosphamide/thalidomide/dexamethasone; DEX, dexamethasone; LEN, lenalidomide; MM, multiple myeloma; MP, melphalan/prednisone; MPR-R, melphalan/prednisone/lenalidomide with lenalidomide maintenance; MPT, melphalan/prednisone/thalidomide; RD, lenalidomide plus low-dose dexamethasone; SCT, stem cell transplantation; THD, thalidomide; TD, thalidomide/dexamethasone; VD, bortezomib/dexamethasone; VAD, vincristine/adriamycin/dexamethasone; VMP, bortezomib/melphalan/prednisone; VTD, bortezomib/thalidomide/dexamethasone.